Adlai Nortye

Company Overview

Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on the development of innovative targeted and immune- modulating cancer therapies, with global R&D centers in the U.S. and China. The Company is advancing a robust oncology pipeline, including AN8025, a trifunctional fusion protein (αPD-L1/Lag3v/CD86v) acting as a T cell and antigen-presenting cell modulator, AN9025, an oral small molecule pan-RAS(ON) inhibitor, and AN4005, an oral small molecule PD-L1 inhibitor.

Differentiated Pipeline

We have identified and developed a robust pipeline. Currently, our pipeline includes two IND-enabling stage candidates, AN8025 (tri-specific immune-oncology modulator) and AN9025 (pan-RAS(ON) inhibitor); as well as one clinical-stage drug candidate, AN4005 (oral anti-PD-L1).